European Union: EMA Approval and Member-State Access Differences
The EMA approves GLP-1 drugs at the EU level, but pricing, reimbursement, and day-to-day access still vary significantly by member state.
By the GLP Semaglutide editorial team · Last updated May 10, 2026
In the EU, the European Medicines Agency (EMA) evaluates and authorizes medicines centrally, and a positive opinion leads to a single marketing authorization valid across all EU member states. Semaglutide products (Ozempic, Wegovy, Rybelsus) and tirzepatide (Mounjaro) hold EU-wide marketing authorizations.
Reimbursement is national, not EU-wide
Marketing authorization doesn't guarantee reimbursement. Each member state's health system separately decides whether and how to reimburse a drug, which is why out-of-pocket cost and public-system access for the same EMA-approved product can differ substantially between, say, Germany, France, and Poland.
Supply constraints
The EMA and national regulators have at various points flagged supply constraints for weight-management GLP-1 products and issued guidance prioritizing existing diabetes patients' access during shortages. Country-specific pharmacy and health-ministry sites are the authoritative source for current supply status.
Primary sources